Clinical trial
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome
NCT03703310 is registered in ClinicalTrials.gov with Sol-Gel Technologies, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 19, 2019
- Completion date
- December 28, 2020
- Enrollment
- 174 (actual)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.